S916 Evaluating the Quality and Readability of Online Information Regarding Contraceptive Use in IBD

Abstract

Table 1. Hepatobiliary and pancreatic disorders in CD and UC with anti-TNF therapy Crohn's Disease Ulcerative Colitis Total (Percentage) On Anti-TNF (percentage) OR (95% CI) Total (Percentage) On Anti-TNF (percentage) OR (95% CI) 249,480 39280 209,020 19,860 AIH 590 (0.23%) 120 (0.030%) 1.38 (1.13-1.69) 790 (0.37%) 90 (0.45%) 1.27 (1.02-1.58) CCA 350 (0.14%) 30 (0.07%) 0.50 (0.34-0.73) 590 (0.28%) 30 (0.15%) 0.52 (0.36-0.75) Cholelithiasis 16420 (6.58%) 1560 (3.97%) 0.88 (0.84-0.93) 13030 (6.23%) 430 (2.16%) 0.88 (0.79-0.97) IP 490 (0.19%) 130 (0.33%) 1.95 (1.59-2.38) 450 (0.21%) 70 (0.35%) 1.79 (1.38-2.31) PVT 1090 (0.43%) 110 (0.28%) 0.61 (0.50-0.74) 1320 (0.63%) 80 (0.40%) 0.65 (0.52-0.81) PSC 200 (0.08%) 20 (0.05%) 0.59 (0.37-0.94) 480 (0.22%) 30 (0.15%) 0.64 (0.44-0.93) Lupus* 210 (0.084%) 60 (0.15%) 2.14 (1.59-2.90) 180 (0.086%) 30 (0.15%) 1.92 (1.29-2.84